Sanyo-Onoda, Japan

Ryoichi Kimura

USPTO Granted Patents = 2 

Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):

Title: Ryoichi Kimura: Innovator in Alzheimer's Disease Treatment

Introduction

Ryoichi Kimura is a notable inventor based in Sanyo-Onoda, Japan. He has made significant contributions to the field of medical research, particularly in the treatment of Alzheimer's disease. With a total of 2 patents, his work focuses on innovative compounds that target amylin receptors.

Latest Patents

Kimura's latest patents revolve around compounds for the treatment of Alzheimer's disease. The disclosures provide amylin receptor antagonist compounds, along with compositions that include these compounds. The methods outlined in his patents detail how to prepare and use these antagonists effectively. Furthermore, the patents describe compositions containing the amylin receptor antagonists aimed at treating, preventing, or ameliorating Alzheimer's disease. A key aspect of this work includes a method for inhibiting the activity of an amylin receptor by administering a therapeutically effective amount of an antagonist to a subject in need.

Career Highlights

Ryoichi Kimura is affiliated with the University of Alberta, where he continues to advance his research in the medical field. His innovative approach to addressing Alzheimer's disease has garnered attention and respect within the scientific community.

Collaborations

Kimura has collaborated with notable colleagues such as James Nieman and Jack Jhamandas. Their combined expertise contributes to the ongoing research and development of effective treatments for Alzheimer's disease.

Conclusion

Ryoichi Kimura's work in developing amylin receptor antagonists represents a promising avenue for Alzheimer's disease treatment. His contributions to medical research highlight the importance of innovation in addressing complex health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…